ADAP

Adaptimmune Therapeutics News

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Adaptimmune Therapeutics PLC ADAP NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.22 -5.26% 3.96 19:10:45
Open Price Low Price High Price Close Price Prev Close
4.16 3.89 4.19 3.95 4.18
more quote information »

Recent News

Date Time Source Heading
6/03/202116:32EDGARStatement of Changes in Beneficial Ownership (4)
5/28/202112:13SEEKAdaptimmune slips as Barclays initiates with an underweight..
5/20/202111:14SEEKAdaptimmune shares rise on mid-stage cancer trial data ahead..
5/19/202117:00GLOBETwo Complete Responses and Response Rate of 41% for People..
5/14/202108:39EDGARCurrent Report Filing (8-k)
5/11/202108:32SEEKAdaptimmune posts pre-clinical data from mesothelin cancer..
5/11/202108:00GLOBEFirst Preclinical Data from Adaptimmune’s Mesothelin HiT..
5/06/202116:19EDGARQuarterly Report (10-q)
5/06/202107:39EDGARCurrent Report Filing (8-k)
5/06/202107:32SEEKAdaptimmune EPS beats by $0.21, misses on revenue
5/06/202107:30GLOBEAdaptimmune Reports First Quarter Financial Results and..
4/27/202116:30GLOBEAdaptimmune to Present First Preclinical Data from its..
4/22/202108:00GLOBEAdaptimmune to Report Q1 2021 Financial Results and Business..
4/08/202108:01EDGARProxy Statement (definitive) (def 14a)
3/29/202108:01EDGARProxy Statement - Notice of Shareholders Meeting..
2/25/202107:38EDGARCurrent Report Filing (8-k)
2/25/202107:32SEEKAdaptimmune EPS beats by $0.19, beats on revenue
2/25/202107:30GLOBEAdaptimmune Reports Fourth Quarter / Full Year 2020..
2/16/202116:16EDGARStatement of Ownership (sc 13g)
2/16/202111:42EDGARSchedule 13g
2/16/202110:04EDGARAmended Statement of Ownership (sc 13g/a)
2/11/202108:00GLOBEAdaptimmune to Report Fourth Quarter/ Full Year 2020..
1/28/202106:37EDGARStatement of Ownership (sc 13g)
12/16/202017:01EDGARCurrent Report Filing (8-k)
11/20/202007:37EDGARCurrent Report Filing (8-k)
11/20/202007:30GLOBEAdaptimmune to Showcase Market Potential for SPEAR T-cell..
11/19/202009:10EDGARCurrent Report Filing (8-k)
11/19/202009:00GLOBEDurable Responses with ADP-A2M4 in Synovial Sarcoma with..
11/12/202008:00GLOBEAdaptimmune to Host Virtual Investor Day on Friday, November..
11/09/202015:18GLOBETwo Confirmed Responses and Five out of Six Patients with..
11/05/202016:20EDGARQuarterly Report (10-q)
11/05/202007:41EDGARCurrent Report Filing (8-k)
11/05/202007:30GLOBEAdaptimmune Reports Q3 Financial Results and Business Update
11/04/202010:42EDGARConfidential Treatment Order (ct Order)
10/22/202008:00GLOBEAdaptimmune to Report Q3 Financial Results and Business..
10/15/202016:48EDGARCurrent Report Filing (8-k)
10/15/202016:40GLOBEAdaptimmune Provides Full Contents of its SITC Abstract for..
10/02/202008:45NNWLife-Saving Advancements, Treatments Delivered by Companies..
8/28/202010:45EDGARCurrent Report Filing (8-k)
8/28/202010:30GLOBEPromising Data from Phase 1 Trial with ADP-A2AFP in Liver..
8/10/202017:02EDGARAutomatic Shelf Registration Statement of Securities of..
8/06/202011:17EDGARQuarterly Report (10-q)
8/06/202007:38EDGARCurrent Report Filing (8-k)
8/06/202007:30GLOBEAdaptimmune Reports Q2 Financial Results and Business Update
7/23/202016:00GLOBEAdaptimmune Granted Access to PRIority MEdicines (PRIME)..
7/22/202008:00GLOBEAdaptimmune to Report Q2 Financial Results and Business..
7/01/202017:13EDGARStatement of Changes in Beneficial Ownership (4)
7/01/202017:10EDGARStatement of Changes in Beneficial Ownership (4)
7/01/202017:10EDGARStatement of Changes in Beneficial Ownership (4)
7/01/202017:10EDGARStatement of Changes in Beneficial Ownership (4)
See more news about this stock »


Your Recent History
NASDAQ
ADAP
Adaptimmun..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.